BR112021016348A2 - Método de produção de uma proteína de fusão ligante-toxina em uma célula de planta ou em uma planta inteira - Google Patents

Método de produção de uma proteína de fusão ligante-toxina em uma célula de planta ou em uma planta inteira

Info

Publication number
BR112021016348A2
BR112021016348A2 BR112021016348A BR112021016348A BR112021016348A2 BR 112021016348 A2 BR112021016348 A2 BR 112021016348A2 BR 112021016348 A BR112021016348 A BR 112021016348A BR 112021016348 A BR112021016348 A BR 112021016348A BR 112021016348 A2 BR112021016348 A2 BR 112021016348A2
Authority
BR
Brazil
Prior art keywords
protein
plant
fusion protein
ligand
polynucleotide encoding
Prior art date
Application number
BR112021016348A
Other languages
English (en)
Inventor
Houry Max
MAGY Bertrand
Original Assignee
Atb Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atb Therapeutics filed Critical Atb Therapeutics
Publication of BR112021016348A2 publication Critical patent/BR112021016348A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

método de produção de uma proteína de fusão ligante-toxina em uma célula de planta ou em uma planta inteira. a presente invenção se refere a um método de produção de uma proteína de fusão aglutinante-toxina compreendendo pelo menos um aglutinante de proteína selecionado a partir do grupo que consiste em um anticorpo, um fragmento de anticorpo ou derivado retendo a capacidade de ligação ao alvo, ou um mimético de anticorpo, opcionalmente, um peptídeo ligante, e pelo menos uma toxina de proteína ou protoxina de proteína. o método compreende as etapas de: contatar uma célula vegetal ou uma planta inteira com um construto de ácido nucleico compreendendo em ligação operacional pelo menos o seguinte (a) pelo menos um polinucleotídeo que codifica para o ligante de proteína, ou uma cadeia de ligação alvo ou domínio do mesmo, e b1) um polinucleotídeo que codifica para um ligante de peptídeo clivável e um polinucleotídeo que codifica para uma toxina de proteína, ou b2) um polinucleotídeo que codifica para uma protoxina de proteína, cuja protoxina compreende um domínio clivável para ativação da mesma, permitindo que o construto se integre no núcleo da célula vegetal, ou de uma ou mais células de toda a planta, e expressando a proteína de fusão codificada pela construção de ácido nucleico.
BR112021016348A 2019-02-18 2020-02-18 Método de produção de uma proteína de fusão ligante-toxina em uma célula de planta ou em uma planta inteira BR112021016348A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157839 2019-02-18
PCT/EP2020/054263 WO2020169620A1 (en) 2019-02-18 2020-02-18 Method of producing a binder-toxin fusion protein in a plant cell or a whole plant

Publications (1)

Publication Number Publication Date
BR112021016348A2 true BR112021016348A2 (pt) 2021-11-23

Family

ID=65717705

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016348A BR112021016348A2 (pt) 2019-02-18 2020-02-18 Método de produção de uma proteína de fusão ligante-toxina em uma célula de planta ou em uma planta inteira

Country Status (10)

Country Link
US (1) US20220090113A1 (pt)
EP (1) EP3927831A1 (pt)
JP (2) JP7150999B2 (pt)
KR (1) KR102398485B1 (pt)
CN (2) CN115925972A (pt)
BR (1) BR112021016348A2 (pt)
CA (1) CA3128793C (pt)
IL (1) IL285719B (pt)
WO (1) WO2020169620A1 (pt)
ZA (1) ZA202105654B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021241719A1 (pt) * 2020-05-28 2021-12-02
US20230310557A1 (en) 2020-08-17 2023-10-05 Atb Therapeutics Recombinant immunotoxin comprising a ribotoxin or rnase
WO2023156634A1 (en) 2022-02-17 2023-08-24 Atb Therapeutics Recombinant immunotoxin comprising a ribosome inactivating protein
CN114605556B (zh) * 2022-03-10 2023-04-14 南开大学 一种增强植物根系募集功能细菌的融合蛋白及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6140075A (en) 1994-07-25 2000-10-31 Monsanto Company Method for producing antibodies and protein toxins in plant cells
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
AU2003210405A1 (en) 2002-03-05 2003-09-16 Artemis Pharmaceuticals Gmbh Inbred embryonic stem-cell derived mice
ATE521367T1 (de) 2002-06-07 2011-09-15 Kentucky Bioproc Llc Flexlibler aufbau- und darreichungs-plattform von impfstoffen
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
WO2009064815A1 (en) * 2007-11-13 2009-05-22 The Scripps Research Institute Production of cytotoxic antibody-toxin fusion in eukaryotic algae
US9586996B2 (en) * 2010-04-30 2017-03-07 Esperance Pharmaceuticals, Inc. Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
WO2011156535A1 (en) 2010-06-09 2011-12-15 E. I. Du Pont De Nemours And Company Regulatory sequences for modulating transgene expression in plants
KR101990341B1 (ko) 2013-03-12 2019-06-19 몰레큘러 템플레이츠, 인코퍼레이션. 세포 내재화를 유도하기 위한 ｃｄ20-결합 면역독소 및 이의 사용 방법
WO2016187585A1 (en) * 2015-05-20 2016-11-24 Viventia Bio Inc. Deimmunized linker and methods of use

Also Published As

Publication number Publication date
JP2022176933A (ja) 2022-11-30
WO2020169620A1 (en) 2020-08-27
JP2022518614A (ja) 2022-03-15
US20220090113A1 (en) 2022-03-24
CA3128793A1 (en) 2020-08-27
KR20210120051A (ko) 2021-10-06
IL285719B (en) 2022-07-01
KR102398485B1 (ko) 2022-05-16
CA3128793C (en) 2023-02-28
JP7150999B2 (ja) 2022-10-11
IL285719A (en) 2021-10-31
CN113728107B (zh) 2022-06-24
CN113728107A (zh) 2021-11-30
CN115925972A (zh) 2023-04-07
ZA202105654B (en) 2023-04-26
EP3927831A1 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
BR112021016348A2 (pt) Método de produção de uma proteína de fusão ligante-toxina em uma célula de planta ou em uma planta inteira
Kosmacz et al. Protein and metabolite composition of Arabidopsis stress granules
Barberon The endodermis as a checkpoint for nutrients
Eskelinen et al. Links between plant community composition, soil organic matter quality and microbial communities in contrasting tundra habitats
Huang et al. Lower incidence and severity of tomato virus in elevated CO2 is accompanied by modulated plant induced defence in tomato
Tausta et al. Developmental dynamics of Kranz cell transcriptional specificity in maize leaf reveals early onset of C4-related processes
Thormaehlen et al. Inactivation of thioredoxin f1 leads to decreased light activation of ADP‐glucose pyrophosphorylase and altered diurnal starch turnover in leaves of Arabidopsis plants
Suorsa et al. Light acclimation involves dynamic re‐organization of the pigment–protein megacomplexes in non‐appressed thylakoid domains
BR122019001711B8 (pt) Composição e método para o controle de pragas de lepidópteros
BRPI0620803B8 (pt) anticorpo isolado ou fragmento de anticorpo anti-her-3, seu processo de preparação, composição farmacêutica e kit compreendendo o mesmo, molécula de ácido nucléico codificando o referido anticorpo, vetor compreendendo o mesmo, microrganismo transgênico, bem como método para diagnosticar uma doença associada a her-3
Chen et al. Stable megadalton TOC–TIC supercomplexes as major mediators of protein import into chloroplasts
BR112012007821A2 (pt) polipeptídeos para ligação ao "receptor de produtos finais de glicação avançada" bem como composições e métodos envolvendo os mesmos
WO2009023517A3 (en) Compositions and methods for detecting and modulating cell death by a translation regulated gene expression system
TR201910348T4 (tr) Matriks metalloproteinaz 9 için antikorlar.
BRPI0709598A8 (pt) composições de polipeptídeos estabilizados
BRPI0914563A8 (pt) método para remover pelo menos um hidrocarboneto aromático policíclico a partir de um material diferente de material de fumo, ou a partir de um material de fumo ou a partir de um derivado do mesmo
BRPI0606399A2 (pt) domìnios de imunoglobulina sintética com propriedades de ligação construìdos em regiões da molécula diferentes das regiões de determinação de complementariedade
BRPI0812878A2 (pt) Anticorpo isolado, sintético ou recombinante ou parte funcional, derivado e/ou análogo do mesmo, sequência de ácido nucleico isolada, sintética ou recombinante, ou uma parte funcional, derivado ou análogo da mesma, usos de um anticorpo, parte funcional, derivado ou análogo e de uma sequência de ácido nucleico, parte funcional, derivado e/ou análogo, célula que produz anticorpo isolado, métodos para produzir uma célula que produz anticorpo, para produzir anticorpos e para tratar ou prevenir pelo menos em parte um distúrbio relacionado com rsv
CL2010001427A1 (es) Proteina de union que comprende una cadena polipeptidica capaz de unir un par de antigenos; acido nucleico aislado que codifica dicha proteina de union; vector y celula huesped; metodo para producir proteina de union; composicion farmaceutica que comprende dicha proteina.
CL2012001626A1 (es) Células de planta que comprenden adn que codifica para las proteínas insecticidas cry1c y cry1f, composición para controlar plagas de lepidópteros que comprende dichas células, y método para manejar el desarrollo de resistencia de un insecto a una toxina cry.
WO2011073214A3 (en) A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
Albulescu et al. A decoy-receptor approach using nicotinic acetylcholine receptor mimics reveals their potential as novel therapeutics against neurotoxic snakebite
BRPI0817447A2 (pt) Molécula de ácido nucleico isolado, planta transformada, semente, célula hospedeira não-humana, métodos para aumentar a resistência de uma planta a pelo menos um patógeno de planta, para expressar um gene de interesse em uma planta ou célula de planta, para expressar genes em alto nível em uma planta ou célula de planta e para causar morte celular em uma parte da planta de interesse, e, polipeptídeo isolado.
George et al. Quantitative proteomic analysis of cabernet sauvignon grape cells exposed to thermal stresses reveals alterations in sugar and phenylpropanoid metabolism
Czubinski et al. Lupin seeds storage protein composition and their interactions with native flavonoids